Clin2
NCT07493317Possibly a fitRecruiting

Tocilizumab for depression with inflammation

Major Depressive Disorder

Treatments studied

Part of Brain & nervous system, Mental health clinical trials.

This trial tests a medication called tocilizumab, which targets inflammation, to see if it can improve symptoms of major depression in people with signs of inflammation. You may be eligible if you have depression with a high monocyte count and significant loss of interest or pleasure.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
60 people
Ages
18 years to 70 years
Study type
Interventional

Who can take part

  • You are between 18 and 70 years old.
  • You have a diagnosis of major depressive disorder (MDD) and are currently in a depressive episode.
  • A blood test shows your monocyte count is 500 or higher (a sign of inflammation).
  • You have lost interest or pleasure in things (score of 20 or more on a standard questionnaire).
  • You have no history of schizophrenia, bipolar disorder, or psychosis.
  • You are not at serious risk of suicide or self-harm.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05644301Recruiting· Phase 3
Blood-marker guided add-on treatment for major depression

This study tests whether doctors can choose the best add-on immune-related treatment for people with major depressive disorder by using inflammation blood tests. It’s meant for people whose depression has not improved enough with their current antidepressant.

Duffel, Antwerpen
NCT06699966Not yet recruiting· Phase 4
Anti-inflammatory trial for depression

This study tests whether two anti-inflammatory drugs, celecoxib and minocycline, can help treat depression. You may join if you have moderate to severe depression and are not at high risk for certain medical conditions or drug interactions.

NCT07003997Recruiting· Phase 2
JAK inhibitor for depression with inflammation

This trial tests a JAK inhibitor (a type of anti-inflammatory drug) for depression that is linked to inflammation. If you have depression or bipolar depression and a high CRP level (a marker of inflammation), you may be eligible.

Atlanta, Georgia
NCT06537921Recruiting
Testing minocycline for depression with obesity

This trial tests whether adding the antibiotic minocycline to your current antidepressant helps people with both depression and obesity. It aims to see if reducing inflammation can improve mood.

London
NCT04751331Recruiting· Phase 1/Phase 2
Study brain response to inflammation in depression

This early-stage study tests how your brain responds to an “inflammatory challenge” in people with major depressive disorder and in healthy volunteers. It may help researchers understand the immune-to-brain link in depression and guide future treatments.

Tulsa, Oklahoma
NCT06450704Recruiting
Exercise for depression: brain and body health

This trial tests if a 12-week exercise program can reduce inflammation and improve brain function in people with depression. It's for adults currently taking antidepressant medication and looking for extra help through physical activity.

Alcalá de Henares, Madrid

Hear when a new Major Depressive Disorder trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.